Gripwise® Versus JAMAR® (HANDGAGES)

November 18, 2021 updated by: Bérengère, University Hospital, Caen

Comparison of Gripstrength Assessment Between the Gripwise® and JAMAR® Dynamometers in Elderly Inpatients

It is recommended to screen ageing patients for sarcopenia, due to the increased risk of morbimortality if detected positive. According to the consensus of the European Working Group on Sarcopenia in Older People, the diagnosis of sarcopenia is based, among other things, on grip strength measurement.

Our study will compare the performance of the new GRIPWISE digital device with the mechanical dynamometer JAMAR, the gold standard currently used to assess the grip strength. We propose to evaluate it in an elderly hospitalized population where the prevalence of sarcopenia is likely to be high due to the high prevalence of various chronic illness, notably oncological and cardiological ones.

This cross-sectional study will include 348 patients.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

348

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Caen, France
        • CAEN University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

aged inpatients hospitalized in CAEN University Hospital

Description

Inclusion Criteria:

  • men and women aged 65 or over
  • affiliated to a health insurance
  • Francophone.

Exclusion Criteria:

  • - refusal to participate
  • unable to communicate
  • unable to use both hands (dominant and non-dominant)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
single group
gripwise or jamar will be randomly assessed first

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison between Jamar® and Gripwise® values for grip strength measurement
Time Frame: day1
Intra-class correlation between the best values obtained with each device
day1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
comparison according to the patient's position
Time Frame: day1
correlations of dynamometer measurements between patients assessed in the sitting or lying position
day1
number of attempt to reach the maximum value
Time Frame: day1
Comparison of the three measurements obtained for each patient with each device
day1
factors influencing detected weakness
Time Frame: day1
significant difference in the rate of women detected as weak with a handgrip <16kg and men <27kg, between the different reasons for hospitalisation, the number of days of hospitalisation, and between the different chronic cancerous and non-cancerous pathologies (Updated Charlson Comorbidity Index), the age groups 65-79 years and ≥80 years
day1
satisfaction using the devices
Time Frame: day1
rate of patients finding one of both device easier to use
day1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Caen

Investigators

  • Principal Investigator: Bérengère Beauplet, MD, Caen UH

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2021

Primary Completion (Actual)

September 1, 2021

Study Completion (Actual)

November 18, 2021

Study Registration Dates

First Submitted

September 22, 2021

First Submitted That Met QC Criteria

September 22, 2021

First Posted (Actual)

September 29, 2021

Study Record Updates

Last Update Posted (Actual)

November 30, 2021

Last Update Submitted That Met QC Criteria

November 18, 2021

Last Verified

November 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2021-A00927-34

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Age-Related Sarcopenia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe